生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

交易中 04-29 10:51:35

5,742.753

-23.985

-0.42%

最高5,795.360	最低5,716.355	成交量5,738万
今开5,763.067	昨收5,766.738	日振幅1.37%
总市值0.00	流通市值0.00	总股本0.00
成交额15.50亿	换手率--	流通股本0.00
市净率6.267177	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5742.753,"timestamp":1777431094869,"preClose":5766.738,"halted":0,"volume":57384362,"delay":0,"changeRate":-0.004159,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-23.984863,"latestTime":"04-29 10:51:35","open":5763.0674,"high":5795.3604,"low":5716.3545,"amount":1549755688,"amplitude":0.0137,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1777435200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1777426200000,1777435200000],[1777438800000,1777449600000]],"pbRate":6.267177,"peRate":-283.905519,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2631555950","title":"大亚圣象：铝板带项目终端应用于医药、食品包装，新能源动力电池，工业电力电子电容器等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2631555950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631555950?lang=zh_cn&edition=full","pubTime":"2026-04-29 09:03","pubTimestamp":1777424584,"startTime":"0","endTime":"0","summary":"证券之星消息，大亚圣象(000910)04月28日在投资者关系平台上答复投资者关心的问题。投资者提问：亲爱的董秘你好，一期铝板已经投产，能简单和我们说一下，生产的铝板主要用于那些行业领域和用途么？大亚圣象回复：您好！铝板带具有质轻、耐蚀、易加工、表面美观等优点，可广泛应用于建筑、包装容器、交通运输等领域。公司一期铝板带项目主要生产高精度双零箔坯料、高性能电池箔坯料，终端应用于医药、食品包装，新能源动力电池，工业电力电子电容器等领域。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900028162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","399941","09939","159938","BK1515","159146","160640","000910","BK1161","000941.SH","159875","BK0245","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630589301","title":"再鼎医药(ZLAB)逆势上涨2.66% 机构指Zoci数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2630589301","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630589301?lang=zh_cn&edition=full","pubTime":"2026-04-28 23:20","pubTimestamp":1777389610,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 逆势上涨2.66%，最新报22.44美元，成交额309.77万美元。机构维持2026年和2027年盈利预测不变，维持跑赢行业评级，且由于Zoci数据积极，机构上调Zoci未来销售峰值，基于DCF模型，上调H股/US股目标价15%/15%至22.0港元/28.4美元，较当前股价有16.8%/24.2%上行空间。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299809","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK4531","BK1574","BK1161","BK4526","BK4139","ZLAB","BK4588","BK4548","BK1588","BK4585","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630585018","title":"永泰生物-B(06978) EAL® 附条件上市申请未获批准 公司将开展确证性研究后重新申报 4月29日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2630585018","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630585018?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:48","pubTimestamp":1777387691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，永泰生物-B 发布公告，先前公司已就EAL用于预防肝癌术后复发向CDE提交附条件上市申请。依据相关法规规定，本次不予批准告知书仅针对附条件批准上市申请，公司将积极开展后续确证性临床研究的准备工作，并在完成相应研究后按常规批准程式重新申报集团核心候选产品EAL的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1161","BK1574","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163264981","title":"永泰生物-B将开展验证性临床研究并计划重新提交EAL申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1163264981","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163264981?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:42","pubTimestamp":1777387332,"startTime":"0","endTime":"0","summary":"永泰生物-B宣布将启动验证性临床研究，为重新提交EAL（早期准入计划）申请做准备。该公司表示，此次临床研究旨在进一步验证其产品的安全性与有效性，为后续的上市申请提供充分的数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124168124","title":"永泰生物-B收到关于Eal药物有条件新药申请被拒通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1124168124","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124168124?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:40","pubTimestamp":1777387231,"startTime":"0","endTime":"0","summary":"永泰生物-B（Immunotech Biopharm Ltd）宣布，公司于2026年4月27日收到有关Eal药物有条件新药申请的拒绝通知书。\n该通知意味着监管机构目前未批准该药物的有条件上市申请。公司表示将评估后续步骤，并考虑是否提出上诉或补充数据重新递交申请。\n此次决定可能对永泰生物-B的新药研发进度产生影响。投资者需关注公司后续动态及官方披露的进一步信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630585691","title":"东曜药业-B(01875)委任李锦才为执行董事、董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2630585691","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630585691?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:30","pubTimestamp":1777386607,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)公布，自2026年4月29日起，付山先生已辞任公司执行董事、董事会主席、提名委员会及战略及ESG委员会成员兼主席;刘卫东博士已辞任公司非执行董事、审计与关联方交易审核委员会及战略及ESG委员会成员;孙晖女士已辞任公司独立非执行董事、审计与关联方交易审核委员会成员兼主席及提名委员会成员;张勍先生已辞任公司独立非执行董事、审计与关联方交易审核委员会成员及薪酬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164905468","title":"东曜药业-B任命李金才博士为执行董事兼董事会主席","url":"https://stock-news.laohu8.com/highlight/detail?id=1164905468","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164905468?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:29","pubTimestamp":1777386552,"startTime":"0","endTime":"0","summary":"东曜药业-B宣布，正式委任李金才博士担任公司执行董事及董事会主席职务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630889705","title":"华昊中天医药-B(02563)建议委任朱晓东为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2630889705","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630889705?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:52","pubTimestamp":1777384324,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B(02563)发布公告，孟颂东博士因其主要雇主的要求已向本公司呈辞本公司独立非执行董事、薪酬与考核委员会主席及审计委员会成员职务，自2026年4月29日起生效。董事会已决议建议委任朱晓东博士为第二届董事会的独立非执行董事，任期将于第二届届满日期结束，惟须待股东于本公司股东周年大会上通过相关决议案后，方可作实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","09939","159938","02563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630300751","title":"博安生物(06955)建议采纳限制性股票单位激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2630300751","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630300751?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:35","pubTimestamp":1777383310,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，于2026年4月28日，董事会议决建议就本公司H股采纳限制性股票单位激励计划(限制性股票单位激励计划)。限制性股票单位激励计划旨在进一步完善本公司的长效人才激励架构，激励核心雇员为本公司的发展作出贡献，促进本公司股东、本公司及管理团队间的利益更趋一致，从而助力本公司持续及稳定长期的发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630408304","title":"和誉-B(02256.HK)完成配售4290万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630408304","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630408304?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:27","pubTimestamp":1777379222,"startTime":"0","endTime":"0","summary":"格隆汇4月28日丨和誉-B(02256.HK)公告，公司欣然宣布，配售已于2026年4月28日完成。合共4290万股新股份已按配售价每股股份12.18港元成功配售予不少于六(6)名承配人，据董事经作出一切合理查询后所知、所悉及所信，该等承配人连同彼等各自的最终实益拥有人均为独立第三方。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260428/32185159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2476274308.USD","LU2778985437.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","02256","BK1161","LU2488822045.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630025983","title":"迈威生物2026年第一季度净亏损2.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630025983","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630025983?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:24","pubTimestamp":1777379083,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩宋雨盈）4月28日，迈威生物发布2026年第一季度报告，报告期内，公司实现营业收入1.28亿元，同比增长184.89%；归属于上市公司股东的净亏损为2.42亿元，上年同期为亏损2.92亿元；归属于上市公司股东的扣除非经常性损益的净亏损为2.42亿元，上年同期为亏损2.93亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283722717414.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283722717414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688062","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630309173","title":"复宏汉霖(02696)自主研发的POHERDY®于欧盟获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2630309173","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630309173?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:50","pubTimestamp":1777377048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，公司自主研发的POHERDY 420mg/14mL注射液的上市许可申请 已获欧盟委员会批准，该商品名由N.V. Organon于欧盟注册商标。此次获批意味着POHERDY 在所有欧盟成员国及冰岛、列支敦士登和挪威获得集中上市许可。继于美国获批上市之后，此次POHERDY于欧盟获批上市，是集团产品在国际主流市场获得的又一认可，将进一步推进公司国际化布局的进程，提升公司产品的国际影响力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","FSXEmain","BK1161","HK0000306701.USD","HK0000320264.USD","IPOS","HK0000320223.HKD","FESXmain","HK0000306685.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128740396","title":"复宏汉霖旗下汉曲优®获欧盟批准用于治疗HER2阳性早期及转移性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740396","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128740396?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:49","pubTimestamp":1777376981,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司近日宣布，其核心产品汉曲优®（通用名：曲妥珠单抗）已获得欧盟委员会批准，用于治疗HER2阳性早期乳腺癌及转移性乳腺癌。此项批准标志着公司创新研发成果获得国际主流市场认可，为欧洲患者提供了重要的治疗选择。\nHER2阳性乳腺癌是一种侵袭性较强的乳腺癌亚型，汉曲优®作为曲妥珠单抗的生物类似药，在疗效与安全性方面与原研药高度相似。此次获批将进一步提升复宏汉霖在全球生物药市场的竞争力，并为其国际化战略注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","HK0000306701.USD","BK1161","HK0000320264.USD","HK0000320223.HKD","02696","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306320","title":"亿腾嘉和(06998)4月28日斥资335.3万港元回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306320","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630306320?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:25","pubTimestamp":1777375537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿腾嘉和(06998)发布公告，于2026年4月28日斥资335.3万港元回购100万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","06998","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185513701","title":"九源基因Jy54注射液获中国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1185513701","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185513701?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:21","pubTimestamp":1777375270,"startTime":"0","endTime":"0","summary":"杭州九源基因工程股份有限公司宣布，其研发的Jy54注射液已正式获得中国国家药品监督管理局的临床试验默示许可。该生物制品即将开展针对特定适应症的临床研究，标志着公司创新药研发管线取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630030689","title":"FIDELITY CHINA SPECIAL SITUATIONS PLC增持科笛-B(02487)3.06万股 每股作价4.6041港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630030689","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630030689?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:18","pubTimestamp":1777375115,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，4月23日，FIDELITY CHINA SPECIAL SITUATIONS PLC增持科笛-B(02487)3.06万股，每股作价4.6041港元，总金额约为14.09万港元。增持后最新持股数目约为1826.09万股，最新持股比例为5.01%。本交易涉及其他关联方：FIL Limited、Pandanus Associates Inc.、Pandanus Partners L.P.。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151450629","title":"九源基因Jy54注射液获国家药监局批准在中国开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1151450629","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151450629?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:20","pubTimestamp":1777371634,"startTime":"0","endTime":"0","summary":"杭州九源基因工程股份有限公司宣布，其研发的Jy54注射液已正式获得中国国家药品监督管理局（NMPA）的临床试验批准。该批准标志着Jy54注射液可在国内进入临床研究阶段，为公司创新药管线的发展注入新动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630937793","title":"昊海生物科技(06826)4月28日斥资401.59万港元回购18.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630937793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630937793?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:09","pubTimestamp":1777370997,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，该公司于2026年4月28日斥资401.59万港元回购18.06万股股份，每股回购价格为21.92-22.4港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","06826","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630237170","title":"昊海生物科技(06826)拟派发末期股息每股0.6元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630237170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630237170?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:32","pubTimestamp":1777368756,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，该公司拟派发末期股息每股0.6元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","BK1593","BK4585","VIG","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630799123","title":"康希诺生物(06185)一季度归母净亏损4042.43万元 同比扩大250.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630799123","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630799123?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:59","pubTimestamp":1777366795,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物(06185)发布截至2026年3月31日止3个月业绩，营业收入1.9亿元(人民币，下同)，同比增加38.73%;归属于上市公司股东的净亏损4042.43万元，同比扩大250.13%;每股基本亏损0.16元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"530716c61aaa22cfcffdb04a123fa588","theme_name":"热榜No.22 · 2026年第一季度多家公司财报披露及业绩下滑情况","theme_type":2,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"康希诺生物(06185)一季度归母净亏损4042.43万元 同比扩大250.13%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06185","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":0.0292},{"period":"3month","weight":-0.0772},{"period":"6month","weight":-0.0229},{"period":"1year","weight":0.1688},{"period":"ytd","weight":0.0019}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}